XML 69 R54.htm IDEA: XBRL DOCUMENT
v3.19.2

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2019 | Jul. 01, 2018 | Jun. 30, 2019 | Jul. 01, 2018
Sales by segment of business |  |  |  |
Sales to customers | $ 20,562 | $ 20,830 | $ 40,583 | $ 40,839
Percent Change (as a percent) | (1.30%) |  | (0.60%) |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10,403 | 10,640 | $ 20,532 | 20,591
Percent Change (as a percent) | (2.20%) |  | (0.30%) |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10,159 | 10,190 | $ 20,051 | 20,248
Percent Change (as a percent) | (0.30%) |  | (1.00%) |
CONSUMER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,544 | 3,504 | $ 6,862 | 6,902
Percent Change (as a percent) | 1.20% |  | (0.60%) |
CONSUMER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,537 | 1,476 | $ 2,975 | 2,912
Percent Change (as a percent) | 4.10% |  | 2.20% |
CONSUMER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,007 | 2,028 | $ 3,887 | 3,990
Percent Change (as a percent) | (1.00%) |  | (2.60%) |
CONSUMER | Baby Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 443 | 456 | $ 837 | 913
Percent Change (as a percent) | (2.80%) |  | (8.40%) |
CONSUMER | Baby Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 99 | 89 | $ 186 | 186
Percent Change (as a percent) | 11.50% |  | (0.20%) |
CONSUMER | Baby Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 344 | 367 | $ 651 | 727
Percent Change (as a percent) | (6.30%) |  | (10.50%) |
CONSUMER | Beauty |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,202 | 1,109 | $ 2,292 | 2,193
Percent Change (as a percent) | 8.40% |  | 4.50% |
CONSUMER | Beauty | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 663 | 637 | $ 1,251 | 1,248
Percent Change (as a percent) | 4.10% |  | 0.30% |
CONSUMER | Beauty | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 539 | 472 | $ 1,041 | 945
Percent Change (as a percent) | 14.10% |  | 10.10% |
CONSUMER | Oral Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 389 | 393 | $ 756 | 772
Percent Change (as a percent) | (1.10%) |  | (2.00%) |
CONSUMER | Oral Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 155 | 157 | $ 306 | 314
Percent Change (as a percent) | (1.60%) |  | (2.50%) |
CONSUMER | Oral Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 234 | 236 | $ 450 | 458
Percent Change (as a percent) | (0.70%) |  | (1.70%) |
CONSUMER | OTC |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,064 | 1,066 | $ 2,151 | 2,138
Percent Change (as a percent) | (0.10%) |  | 0.60% |
CONSUMER | OTC | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 484 | 454 | $ 991 | 919
Percent Change (as a percent) | 6.60% |  | 7.80% |
CONSUMER | OTC | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 580 | 612 | $ 1,160 | 1,219
Percent Change (as a percent) | (5.10%) |  | (4.90%) |
CONSUMER | Women's Health |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 253 | 280 | $ 478 | 523
Percent Change (as a percent) | (9.50%) |  | (8.50%) |
CONSUMER | Women's Health | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 4 | $ 6 | 7
Percent Change (as a percent) | (10.30%) |  | (3.70%) |
CONSUMER | Women's Health | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 250 | 276 | $ 472 | 516
Percent Change (as a percent) | (9.50%) |  | (8.60%) |
CONSUMER | Wound Care/Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 193 | 200 | $ 348 | 363
Percent Change (as a percent) | (3.40%) |  | (4.00%) |
CONSUMER | Wound Care/Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 132 | 135 | $ 234 | 238
Percent Change (as a percent) | (1.90%) |  | (1.50%) |
CONSUMER | Wound Care/Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 61 | 65 | $ 114 | 125
Percent Change (as a percent) | (6.40%) |  | (8.90%) |
PHARMACEUTICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10,529 | 10,354 | $ 20,773 | 20,198
Percent Change (as a percent) | 1.70% |  | 2.80% |
PHARMACEUTICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5,783 | 5,899 | $ 11,365 | 11,253
Percent Change (as a percent) | (2.00%) |  | 1.00% |
PHARMACEUTICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,746 | 4,455 | $ 9,408 | 8,945
Percent Change (as a percent) | 6.50% |  | 5.20% |
PHARMACEUTICAL | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,466 | 3,338 | $ 6,717 | 6,380
Percent Change (as a percent) | 3.80% |  | 5.30% |
PHARMACEUTICAL | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,379 | 2,317 | $ 4,542 | 4,317
Percent Change (as a percent) | 2.70% |  | 5.20% |
PHARMACEUTICAL | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,087 | 1,021 | $ 2,175 | 2,063
Percent Change (as a percent) | 6.30% |  | 5.40% |
PHARMACEUTICAL | Immunology | REMICADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,107 | 1,320 | $ 2,209 | 2,709
Percent Change (as a percent) | (16.20%) |  | (18.50%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 801 | 918 | $ 1,575 | 1,834
Percent Change (as a percent) | (12.70%) |  | (14.10%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 62 | 104 | $ 138 | 246
Percent Change (as a percent) | (40.30%) |  | (43.90%) |
PHARMACEUTICAL | Immunology | REMICADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 244 | 298 | $ 496 | 629
Percent Change (as a percent) | (18.50%) |  | (21.20%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 563 | 548 | $ 1,087 | 1,066
Percent Change (as a percent) | 2.70% |  | 1.90% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 281 | 274 | $ 544 | 498
Percent Change (as a percent) | 2.70% |  | 9.10% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 282 | 274 | $ 543 | 568
Percent Change (as a percent) | 2.70% |  | (4.40%) |
PHARMACEUTICAL | Immunology | STELARA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,558 | 1,341 | $ 2,963 | 2,402
Percent Change (as a percent) | 16.10% |  | 23.30% |
PHARMACEUTICAL | Immunology | STELARA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,058 | 919 | $ 1,940 | 1,571
Percent Change (as a percent) | 15.20% |  | 23.50% |
PHARMACEUTICAL | Immunology | STELARA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 499 | 422 | $ 1,022 | 831
Percent Change (as a percent) | 18.10% |  | 23.00% |
PHARMACEUTICAL | Immunology | TREMFYA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 235 | 126 | $ 452 | 198
Percent Change (as a percent) | 86.50% |  |  |
PHARMACEUTICAL | Immunology | TREMFYA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 176 | 102 | 344 | 168
Percent Change (as a percent) | 72.30% |  |  |
PHARMACEUTICAL | Immunology | TREMFYA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 59 | 24 | 108 | 30
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 3 | $ 6 | 5
Percent Change (as a percent) | 27.70% |  | 23.60% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 3 | $ 6 | 5
Percent Change (as a percent) | 27.70% |  | 23.60% |
PHARMACEUTICAL | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 862 | 849 | $ 1,708 | 1,679
Percent Change (as a percent) | 1.50% |  | 1.70% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 387 | 328 | $ 744 | 661
Percent Change (as a percent) | 17.80% |  | 12.50% |
PHARMACEUTICAL | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 475 | 521 | $ 964 | 1,018
Percent Change (as a percent) | (8.70%) |  | (5.30%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 210 | 211 | $ 421 | 421
Percent Change (as a percent) | (0.60%) |  | 0.10% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 12 | 15 | $ 24 | 29
Percent Change (as a percent) | (15.80%) |  | (17.30%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 198 | 196 | $ 397 | 392
Percent Change (as a percent) | 0.50% |  | 1.40% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 535 | 492 | $ 1,058 | 970
Percent Change (as a percent) | 8.70% |  | 9.10% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 344 | 277 | $ 659 | 550
Percent Change (as a percent) | 24.20% |  | 19.90% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 191 | 215 | $ 399 | 420
Percent Change (as a percent) | (11.10%) |  | (5.00%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 117 | 146 | $ 229 | 288
Percent Change (as a percent) | (19.70%) |  | (20.70%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 31 | 36 | $ 61 | 82
Percent Change (as a percent) | (16.60%) |  | (26.00%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 86 | 110 | $ 168 | 206
Percent Change (as a percent) | (20.80%) |  | (18.60%) |
PHARMACEUTICAL | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,538 | 1,528 | $ 3,167 | 3,087
Percent Change (as a percent) | 0.60% |  | 2.60% |
PHARMACEUTICAL | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 664 | 639 | $ 1,387 | 1,263
Percent Change (as a percent) | 3.80% |  | 9.80% |
PHARMACEUTICAL | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 875 | 889 | $ 1,780 | 1,824
Percent Change (as a percent) | (1.60%) |  | (2.40%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 137 | 183 | $ 351 | 356
Percent Change (as a percent) | (25.20%) |  | (1.60%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 15 | 68 | $ 112 | 134
Percent Change (as a percent) | (78.60%) |  | (16.40%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 123 | 115 | $ 239 | 222
Percent Change (as a percent) | 6.20% |  | 7.30% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 818 | 720 | $ 1,608 | 1,416
Percent Change (as a percent) | 13.60% |  | 13.60% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 506 | 438 | $ 989 | 838
Percent Change (as a percent) | 15.60% |  | 18.10% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 312 | 282 | $ 619 | 578
Percent Change (as a percent) | 10.40% |  | 7.00% |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 182 | 188 | $ 361 | 384
Percent Change (as a percent) | (3.40%) |  | (6.20%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 81 | 80 | $ 158 | 162
Percent Change (as a percent) | 0.80% |  | (3.00%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 101 | 108 | $ 203 | 222
Percent Change (as a percent) | (6.50%) |  | (8.40%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 401 | 437 | $ 847 | 931
Percent Change (as a percent) | (8.10%) |  | (8.90%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 62 | 53 | $ 128 | 129
Percent Change (as a percent) | 16.10% |  | (0.40%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 340 | 384 | $ 719 | 802
Percent Change (as a percent) | (11.50%) |  | (10.30%) |
PHARMACEUTICAL | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,697 | 2,456 | $ 5,215 | 4,767
Percent Change (as a percent) | 9.80% |  | 9.40% |
PHARMACEUTICAL | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,013 | 1,085 | $ 1,975 | 2,018
Percent Change (as a percent) | (6.60%) |  | (2.10%) |
PHARMACEUTICAL | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,684 | 1,371 | $ 3,240 | 2,749
Percent Change (as a percent) | 22.80% |  | 17.90% |
PHARMACEUTICAL | Oncology | DARZALEX® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 774 | 511 | $ 1,403 | 943
Percent Change (as a percent) | 51.60% |  | 48.80% |
PHARMACEUTICAL | Oncology | DARZALEX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 369 | 298 | $ 721 | 562
Percent Change (as a percent) | 24.40% |  | 28.50% |
PHARMACEUTICAL | Oncology | DARZALEX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 405 | 213 | $ 682 | 381
Percent Change (as a percent) | 89.50% |  | 78.70% |
PHARMACEUTICAL | Oncology | IMBRUVICA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 831 | 620 | $ 1,615 | 1,207
Percent Change (as a percent) | 34.10% |  | 33.80% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 367 | 250 | $ 716 | 477
Percent Change (as a percent) | 47.00% |  | 50.20% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 463 | 370 | $ 898 | 730
Percent Change (as a percent) | 25.30% |  | 23.10% |
PHARMACEUTICAL | Oncology | VELCADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 224 | 280 | $ 487 | 593
Percent Change (as a percent) | (20.10%) |  | (17.90%) |
PHARMACEUTICAL | Oncology | VELCADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Oncology | VELCADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 224 | 280 | $ 487 | 593
Percent Change (as a percent) | (20.10%) |  | (17.90%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 698 | 909 | $ 1,377 | 1,754
Percent Change (as a percent) | (23.30%) |  | (21.50%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 198 | 486 | $ 383 | 893
Percent Change (as a percent) | (59.40%) |  | (57.10%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 500 | 423 | $ 994 | 861
Percent Change (as a percent) | 18.00% |  | 15.40% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 170 | 136 | $ 333 | 270
Percent Change (as a percent) | 24.70% |  | 23.20% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 78 | 51 | $ 154 | 86
Percent Change (as a percent) | 50.50% |  | 77.70% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 92 | 85 | $ 179 | 184
Percent Change (as a percent) | 8.80% |  | (2.50%) |
PHARMACEUTICAL | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 690 | 665 | $ 1,346 | 1,250
Percent Change (as a percent) | 3.80% |  | 7.70% |
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 439 | 429 | $ 869 | 790
Percent Change (as a percent) | 2.20% |  | 10.00% |
PHARMACEUTICAL | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 251 | 236 | $ 477 | 460
Percent Change (as a percent) | 6.70% |  | 3.70% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 348 | 311 | $ 654 | 582
Percent Change (as a percent) | 12.30% |  | 12.50% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 203 | 180 | $ 375 | 329
Percent Change (as a percent) | 12.80% |  | 14.20% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 146 | 131 | $ 279 | 253
Percent Change (as a percent) | 11.50% |  | 10.30% |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 103 | 143 | $ 220 | 283
Percent Change (as a percent) | (28.00%) |  | (22.40%) |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 41 | 71 | $ 102 | 139
Percent Change (as a percent) | (41.80%) |  | (26.30%) |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 62 | 72 | $ 118 | 144
Percent Change (as a percent) | (14.50%) |  | (18.70%) |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 203 | 171 | $ 401 | 311
Percent Change (as a percent) | 18.20% |  | 28.70% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 175 | 155 | $ 351 | 279
Percent Change (as a percent) | 13.40% |  | 25.90% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 28 | 16 | $ 50 | 32
Percent Change (as a percent) | 62.50% |  | 53.10% |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 37 | 40 | $ 72 | 74
Percent Change (as a percent) | (9.60%) |  | (3.40%) |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 20 | 23 | $ 41 | 43
Percent Change (as a percent) | (18.20%) |  | (8.40%) |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 16 | 17 | $ 31 | 31
Percent Change (as a percent) | 3.70% |  | 4.10% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,275 | 1,518 | $ 2,620 | 3,035
Percent Change (as a percent) | (16.00%) |  | (13.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 902 | 1,101 | $ 1,849 | 2,204
Percent Change (as a percent) | (18.10%) |  | (16.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 373 | 417 | $ 771 | 831
Percent Change (as a percent) | (10.50%) |  | (7.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 549 | 679 | $ 1,091 | 1,257
Percent Change (as a percent) | (19.20%) |  | (13.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 549 | 679 | $ 1,091 | 1,257
Percent Change (as a percent) | (19.20%) |  | (13.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 177 | 215 | $ 379 | 463
Percent Change (as a percent) | (17.90%) |  | (18.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 132 | 169 | $ 286 | 373
Percent Change (as a percent) | (21.20%) |  | (23.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 43 | 46 | $ 92 | 90
Percent Change (as a percent) | (6.00%) |  | 2.60% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 183 | 236 | $ 409 | 512
Percent Change (as a percent) | (22.70%) |  | (20.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 113 | 156 | $ 261 | 345
Percent Change (as a percent) | (27.50%) |  | (24.30%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 70 | 80 | $ 148 | 167
Percent Change (as a percent) | (13.40%) |  | (11.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 368 | 388 | $ 742 | 803
Percent Change (as a percent) | (5.50%) |  | (7.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 107 | 97 | $ 211 | 229
Percent Change (as a percent) | 9.30% |  | (8.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 260 | 291 | $ 531 | 574
Percent Change (as a percent) | (10.50%) |  | (7.50%) |
MEDICAL DEVICES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,489 | 6,972 | $ 12,948 | 13,739
Percent Change (as a percent) | (6.90%) |  | (5.70%) |
MEDICAL DEVICES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,083 | 3,265 | $ 6,192 | 6,426
Percent Change (as a percent) | (5.60%) |  | (3.60%) |
MEDICAL DEVICES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,406 | 3,707 | $ 6,756 | 7,313
Percent Change (as a percent) | (8.10%) |  | (7.60%) |
MEDICAL DEVICES | Diabetes Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 355 | $ 0 | 694
MEDICAL DEVICES | Diabetes Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 0 | 129 | 0 | 246
MEDICAL DEVICES | Diabetes Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 0 | 226 | 0 | 448
MEDICAL DEVICES | Interventional Solutions |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 750 | 667 | $ 1,482 | 1,307
Percent Change (as a percent) | 12.60% |  | 13.40% |
MEDICAL DEVICES | Interventional Solutions | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 366 | 323 | $ 709 | 627
Percent Change (as a percent) | 13.70% |  | 13.20% |
MEDICAL DEVICES | Interventional Solutions | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 385 | 344 | $ 774 | 680
Percent Change (as a percent) | 11.60% |  | 13.70% |
MEDICAL DEVICES | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,224 | 2,262 | $ 4,428 | 4,512
Percent Change (as a percent) | (1.60%) |  | (1.90%) |
MEDICAL DEVICES | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,331 | 1,332 | $ 2,649 | 2,639
Percent Change (as a percent) | (0.10%) |  | 0.40% |
MEDICAL DEVICES | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 894 | 930 | $ 1,779 | 1,873
Percent Change (as a percent) | (3.80%) |  | (5.00%) |
MEDICAL DEVICES | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 364 | 360 | $ 725 | 723
Percent Change (as a percent) | 0.90% |  | 0.30% |
MEDICAL DEVICES | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 216 | 211 | $ 429 | 420
Percent Change (as a percent) | 2.10% |  | 2.10% |
MEDICAL DEVICES | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 147 | 149 | $ 295 | 303
Percent Change (as a percent) | (0.70%) |  | (2.30%) |
MEDICAL DEVICES | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 372 | 382 | $ 741 | 769
Percent Change (as a percent) | (2.80%) |  | (3.70%) |
MEDICAL DEVICES | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 218 | 229 | $ 441 | 457
Percent Change (as a percent) | (4.80%) |  | (3.50%) |
MEDICAL DEVICES | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 153 | 153 | $ 299 | 312
Percent Change (as a percent) | 0.40% |  | (4.00%) |
MEDICAL DEVICES | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 672 | 675 | $ 1,357 | 1,371
Percent Change (as a percent) | (0.60%) |  | (1.00%) |
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 407 | 394 | $ 824 | 801
Percent Change (as a percent) | 3.30% |  | 2.90% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 265 | 281 | $ 533 | 570
Percent Change (as a percent) | (5.90%) |  | (6.50%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 818 | 845 | $ 1,606 | 1,649
Percent Change (as a percent) | (3.10%) |  | (2.60%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 490 | 498 | $ 955 | 961
Percent Change (as a percent) | (1.50%) |  | (0.60%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 328 | 347 | $ 651 | 688
Percent Change (as a percent) | (5.30%) |  | (5.40%) |
MEDICAL DEVICES | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,353 | 2,515 | $ 4,748 | 4,938
Percent Change (as a percent) | (6.50%) |  | (3.90%) |
MEDICAL DEVICES | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 926 | 1,022 | $ 1,927 | 2,015
Percent Change (as a percent) | (9.50%) |  | (4.40%) |
MEDICAL DEVICES | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,427 | 1,493 | $ 2,821 | 2,923
Percent Change (as a percent) | (4.40%) |  | (3.50%) |
MEDICAL DEVICES | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,029 | 1,005 | $ 2,009 | 1,971
Percent Change (as a percent) | 2.30% |  | 1.90% |
MEDICAL DEVICES | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 396 | 402 | $ 800 | 795
Percent Change (as a percent) | (1.70%) |  | 0.60% |
MEDICAL DEVICES | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 633 | 603 | $ 1,209 | 1,176
Percent Change (as a percent) | 5.00% |  | 2.80% |
MEDICAL DEVICES | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,119 | 1,169 | $ 2,208 | 2,296
Percent Change (as a percent) | (4.30%) |  | (3.90%) |
MEDICAL DEVICES | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 443 | 436 | $ 868 | 859
Percent Change (as a percent) | 1.60% |  | 1.00% |
MEDICAL DEVICES | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 674 | 733 | $ 1,339 | 1,437
Percent Change (as a percent) | (7.90%) |  | (6.80%) |
MEDICAL DEVICES | Surgery | SPECIALTY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 206 | 341 | $ 531 | 671
Percent Change (as a percent) | (39.60%) |  | (20.80%) |
MEDICAL DEVICES | Surgery | SPECIALTY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 87 | 184 | $ 259 | 361
Percent Change (as a percent) | (53.10%) |  | (28.30%) |
MEDICAL DEVICES | Surgery | SPECIALTY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 120 | 157 | $ 273 | 310
Percent Change (as a percent) | (23.70%) |  | (12.10%) |
MEDICAL DEVICES | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,161 | 1,173 | $ 2,290 | 2,288
Percent Change (as a percent) | (1.00%) |  | 0.10% |
MEDICAL DEVICES | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 461 | 459 | $ 907 | 899
Percent Change (as a percent) | 0.40% |  | 1.00% |
MEDICAL DEVICES | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 701 | 714 | $ 1,383 | 1,389
Percent Change (as a percent) | (2.00%) |  | (0.50%) |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 842 | 844 | $ 1,666 | 1,651
Percent Change (as a percent) | (0.30%) |  | 0.90% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 333 | 320 | $ 654 | 629
Percent Change (as a percent) | 3.90% |  | 4.00% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 509 | 524 | $ 1,011 | 1,022
Percent Change (as a percent) | (2.90%) |  | (1.00%) |
MEDICAL DEVICES | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 319 | 329 | $ 624 | 637
Percent Change (as a percent) | (2.80%) |  | (2.00%) |
MEDICAL DEVICES | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 128 | 139 | $ 253 | 270
Percent Change (as a percent) | (7.70%) |  | (6.10%) |
MEDICAL DEVICES | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 191 | $ 190 | $ 371 | $ 367
Percent Change (as a percent) | 0.70% |  | 1.00% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_VELCADEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRACLEERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPECIALTYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |